U.S. regulators are planning to review and authorize Pfizer and BioNTech's COVID-19 vaccine for children younger than 5 before data on a third and potentially necessary shot is available.
Pfizer and BioNTech on Tuesday launched a clinical study to evaluate the safety and efficacy of a COVID-19 vaccine that targets omicron, the globally dominant variant.
Pfizer and BioNTech on Tuesday launched a clinical study to evaluate the safety and efficacy of a COVID-19 vaccine that targets omicron, the globally dominant variant.